Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:58:08 EDT Thu 19 Sep 2024
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:IPHA - INNATE PHARMA SPON ADS EACH REP 1 ORD SHS - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IPHA - Q1.52.23·2.320.52.25    3.15  1.8104:00:27Sep 1215 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
04:00:27Q2.24-0.01498
04:00:26Q2.24-0.01108
04:00:26Q2.24-0.01200
04:00:26Q2.25 19
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-09-12 01:00U:IPHANews ReleaseInnate Pharma Reports First Half 2024 Business Update and Financial Results
2024-09-09 01:00U:IPHANews ReleaseInnate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
2024-09-05 01:00U:IPHANews ReleaseInnate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update
2024-09-04 01:00U:IPHANews ReleaseInnate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference
2024-08-01 01:00U:IPHANews ReleaseInnate Pharma Announces Its Participation in Upcoming Investor Conference
2024-06-18 01:00U:IPHANews ReleaseNumber of Shares and Voting Rights of Innate Pharma as of June 10, 2024
2024-06-17 01:00U:IPHANews ReleaseInnate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
2024-06-04 01:00U:IPHANews ReleaseInnate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
2024-05-28 01:00U:IPHANews ReleaseInnate Pharma Announces Its Participation in Upcoming Investor Conferences
2024-05-24 01:00U:IPHANews ReleaseInnate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
2024-05-23 16:00U:IPHANews ReleaseOutcome of Innate Pharma's 2024 Annual General Meeting
2024-05-21 01:00U:IPHANews ReleaseInnate Pharma: Clarification Regarding SAR443579 Designation
2024-05-15 01:00U:IPHANews ReleaseInnate Pharma Highlights Abstracts Selected for EHA 2024 Congress
2024-05-14 01:00U:IPHANews ReleaseInnate Pharma Reports First Quarter 2024 Business Update and Financial Results
2024-05-07 01:00U:IPHANews ReleaseInnate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
2024-04-15 01:00U:IPHANews ReleaseInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
2024-04-15 01:00U:IPHANews ReleaseInnate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
2024-04-10 01:00U:IPHANews ReleaseInnate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
2024-04-09 01:00U:IPHANews ReleaseInnate Pharma Announces Its Participation in Upcoming Investor Conference
2024-04-05 03:34U:IPHANews ReleaseInnate Pharma Files Its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-F